Management Team

Andreas Goutopoulos

PhD – CEO

 

Dr. Andreas Goutopoulos brings 20 years of small molecule drug discovery experience to FoRx. He has been involved in the discovery of ten molecules that have entered clinical trials in various therapeutic areas. He served as Head of Chemistry at EMD Serono for over a decade.

Read more

Since 2018, he has been the CSO of Metabomed Ltd., a VC-backed tumor metabolism drug discovery company and as Entrepreneur-In-Residence at M Ventures. In his latter role, he helped in the founding of FoRx, where he is currently acting as interim CEO.

Ulrich Lücking

PhD – Head of Chemistry

 

Ulrich Lücking, PhD, is a drug discovery leader with 20 years of industrial experience in small molecule research. As a project leader and inventor at Bayer AG and Schering AG his efforts were instrumental in the identification of six clinical candidates so far, including the highly potent and selective ATR inhibitor BAY 1895344. During all his path Ulrich has contributed to the exploration of novel chemical space, for instance with his innovative applications of sulfoximines or macrocycles in drug discovery.

Read more

Prior to joining industry, Ulrich studied chemistry at the University of Hannover and at the University of Cambridge. He completed his PhD at the Max Planck Institute for Coal Research in Müllheim an der Ruhr,  and then carried out his post-doctoral training at the Scripps Research Institute in La Jolla.

Sotirios K. Sotiriou

PhD – Head of Biology

 

Sotirios Sotiriou, PhD, is a Molecular Cancer Biologist currently working as the Head of Biology at FoRx Therapeutics. Previously, he worked as a postdoctoral fellow at Dana-Farber Cancer Institute/Harvard Medical School, Broad Institute of MIT and Harvard and University of Geneva. Sotirios received his PhD degree with great distinction in Molecular Biology from the University of Geneva.

Read more

Sotirios completed his undergraduate studies in Biological Applications and Technology at the University of Ioannina. His research interests focus on DNA repair, DNA replication, and the mechanisms underlying genomic instability in human cancers.